Citadel Advisors’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Citadel Advisors’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-24,700	Closed	-$3.26M	–	15782
2025 Q1	$3.26M	Sell	24,700 -7,300	-23%	-$910K	﹤0.01%	4613
2024 Q4	$2.67M	Sell	32,000 -8,500	-21%	-$698K	﹤0.01%	5044
2024 Q3	$2.96M	Sell	40,500 -20,800	-34%	-$1.56M	﹤0.01%	4804
2024 Q2	$4.2M	Sell	61,300 -56,700	-48%	-$3.93M	﹤0.01%	4021
2024 Q1	$8.17M	Buy	118,000 +65,600	+125%	+$4.51M	﹤0.01%	3200
2023 Q4	$3.75M	Buy	52,400 +17,700	+51%	+$1.02M	﹤0.01%	4251
2023 Q3	$1.81M	Buy	34,700 +21,400	+161%	+$1.25M	﹤0.01%	5406
2023 Q2	$842K	Sell	13,300 -25,400	-66%	-$1.58M	﹤0.01%	6817
2023 Q1	$2.1M	Buy	38,700 +700	+2%	+$33.8K	﹤0.01%	5274
2022 Q4	$2.01M	Sell	38,000 -10,300	-21%	-$516K	﹤0.01%	5477
2022 Q3	$2.25M	Sell	48,300 -49,600	-51%	-$2.59M	﹤0.01%	5366
2022 Q2	$5.59M	Buy	97,900 +16,100	+20%	+$913K	﹤0.01%	3589
2022 Q1	$5M	Sell	81,800 -83,300	-50%	-$4.33M	﹤0.01%	4178
2021 Q4	$8.64M	Buy	165,100 +85,800	+108%	+$3.6M	﹤0.01%	3315
2021 Q3	$2.96M	Buy	79,300 +10,700	+16%	+$372K	﹤0.01%	5397
2021 Q2	$2.8M	Buy	68,600 +9,800	+17%	+$362K	﹤0.01%	5770
2021 Q1	$2M	Sell	58,800 -52,300	-47%	-$1.81M	﹤0.01%	6391
2020 Q4	$3.53M	Sell	111,100 -53,100	-32%	-$1.4M	﹤0.01%	4301
2020 Q3	$4.21M	Sell	164,200 -27,000	-14%	-$616K	﹤0.01%	3406
2020 Q2	$4.91M	Buy	191,200 +141,000	+281%	+$2.85M	﹤0.01%	3108
2020 Q1	$772K	Sell	50,200 -460,900	-90%	-$10M	﹤0.01%	5761
2019 Q4	$17.5M	Buy	511,100 +451,900	+763%	+$5.42M	0.01%	1605
2019 Q3	$442K	Sell	59,200 -60,900	-51%	-$584K	﹤0.01%	6954
2019 Q2	$1.56M	Buy	120,100 +12,100	+11%	+$155K	﹤0.01%	4950
2019 Q1	$1.31M	Sell	108,000 -30,300	-22%	-$387K	﹤0.01%	5124
2018 Q4	$1.57M	Buy	138,300 +75,000	+118%	+$1.21M	﹤0.01%	4546
2018 Q3	$1.37M	Buy	63,300 +23,000	+57%	+$481K	﹤0.01%	5012
2018 Q2	$712K	Buy	+40,300	New	+$818K	﹤0.01%	5798
2018 Q1	–	Sell	-11,900	Closed	-$172K	–	8900
2017 Q4	$172K	Sell	11,900 -3,300	-22%	-$51K	﹤0.01%	7206
2017 Q3	$240K	Buy	15,200 +3,300	+28%	+$48.4K	﹤0.01%	6414
2017 Q2	$148K	Sell	11,900 -900	-7%	-$10.4K	﹤0.01%	6749
2017 Q1	$208K	Buy	+12,800	New	+$185K	﹤0.01%	6458
2016 Q4	–	Sell	-19,100	Closed	-$291K	–	7963
2016 Q3	$291K	Sell	19,100 -3,400	-15%	-$137K	﹤0.01%	5710
2016 Q2	$873K	Buy	+22,500	New	+$808K	﹤0.01%	3735
2016 Q1	–	Sell	-3,600	Closed	-$194K	–	8167
2015 Q4	$194K	Sell	3,600 -10,200	-74%	-$514K	﹤0.01%	5846
2015 Q3	$553K	Buy	13,800 +13,100	+1,871%	+$427K	﹤0.01%	4663
2015 Q2	$22K	Buy	+700	New	+$17.7K	﹤0.01%	8112

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Citadel Advisors's ITCI Position: Q2 2025 in Review

Citadel Advisors sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 2,237,131 shares — an estimated $295M sold.

Citadel Advisors first reported a position in ITCI in Q1 2015 and held it in 40 quarters. The position peaked at $295M in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

Citadel Advisors reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
Citadel Advisors sold 2,237,131 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $295M.
Citadel Advisors first reported a position in Intra-Cellular Therapies Inc. in Q1 2015 and held it in 40 quarters.
Citadel Advisors's Intra-Cellular Therapies Inc. position peaked at $295M in Q1 2025.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Citadel Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.